Abstract:Purpose The purpose of this study was to analyze tumor-related complications after ruthenium-106 brachytherapy in patients with uveal melanoma, with respect to local tumor control, insufficient radiation response, enucleation, and metastasis rate. Patients/Methods and Materials This retrospective study included 608 patients treated consecutively with ruthenium-106 brachytherapy between January 2008 and December 2010 at the Department of Ophthalmology, University Hospital Essen. The occurrence of radiation-induced results was analyzed by estimating the risk by applying the Kaplan-Meier method, i.e., the "time to event" analysis. The Cox model test was used for the univariate and multivariate risk factor analyses. The median follow-up was 51 months after primary treatment. Results Tumor recurrence was found in 21 patients (3.5%) and repeated treatment due to insufficient effect after the initial ruthenium-106 brachytherapy was performed in 40 patients (6.6%). The 5-year cumulative risk of recurrence was 4.0% and that of insufficient effect was 7.3%. Thirteen patients (2.1%) underwent a secondary enucleation; 8 because of a local recurrence and 5 because of severe post-brachytherapy complications. The cumulative enucleation risk was 2.3% after 5 years and 2.9% after 10 years, corresponding to eye preservation of 97.7 and 97.1%, respectively. In forty-two patients (7.2%), metastatic disease was diagnosed during the follow-up. The metastatic rate as calculated by the Kaplan-Meier method was 9.0, and 13.1% at 5 and 10 years, respectively. Conclusion Our study demonstrated that ruthenium-106 brachytherapy is an excellent treatment option for achieving local tumor control and eye preservation in well-selected patients. The metastatic rate is in agreement with that of previous studies analyzing small to medium size uveal melanomas. Ziel Das Ziel dieser Studie war die Analyse tumor- und strahlenbedingter Komplikationen nach Ruthenium-106-Brachytherapie bei Patienten mit Aderhautmelanom hinsichtlich lokaler Tumorkontrolle, unzureichender Strahlenreaktion, Enukleationsrate und Metastasierungsrate. Patienten/Methoden und Materialien Diese retrospektive Studie umfasste 608 Patienten, die zwischen Januar 2008 und Dezember 2010 an der Augenklinik des Universitätsklinikums Essen mit Ruthenium-106-Brachytherapie behandelt wurden. Das Auftreten strahleninduzierter Ergebnisse wurde durch Risikoabschätzung mithilfe der Kaplan-Meier-Methode, d. h. der "Time-to-Event"-Analyse, analysiert. Für die univariate und multivariate Risikofaktoranalyse wurde der Cox-Modelltest verwendet. Die mittlere Nachbeobachtungszeit betrug 51 Monate nach der Erstbehandlung. Ergebnisse Bei 21 Patienten (3,5%) wurde ein Tumorrezidiv festgestellt und bei 40 Patienten (6,6%) wurde eine wiederholte Behandlung aufgrund eines unzureichenden Effekts nach der primären Ruthenium-106-Brachytherapie durchgeführt. Das kumulative 5-Jahres-Risiko eines Rezidivs betrug 4,0% und dasjenige eines unzureichenden Effekts 7,3%. 13 Patienten (2,1%) wurden einer sekundären Enukleation unterzogen: 8 wegen eines Lokalrezidivs und 5 wegen schwerer Komplikationen nach der Brachytherapie. Das kumulative Enukleationsrisiko betrug 2,3% nach 5 Jahren und 2,9% nach 10 Jahren, was einer Augenerhaltung von 97,7% bzw. 97,1% entspricht. Bei 42 Patienten (7,2%) wurde während der Nachbeobachtungszeit eine Metastasierung diagnostiziert. Die mithilfe der Kaplan-Meier-Methode berechnete Metastasierungsrate betrug 9,0% bzw. 13,1% nach 5 und 10 Jahren, entsprechend. Fazit Unsere Studie hat gezeigt, dass die Ruthenium-106-Brachytherapie eine hervorragende Behandlungsoption zur Erzielung einer lokalen Tumorkontrolle und zum Augenerhalt bei gut ausgewählten Patienten ist. Die Metastasierungsrate stimmt mit der in früheren Studien überein, in denen kleine bis mittelgroße Aderhautmelanome analysiert wurden. Already known: Plaque brachytherapy has been used for the treatment of UM for almost 60 years and is considered an effective method for local tumor control and eye preservation. The survival benefit for patients with UM treated with brachytherapy is under debate. This retrospective study aimed to investigate the efficacy of ruthenium-106 brachytherapy. Newly described: This retrospective study aimed to investigate the efficacy of ruthenium-106 brachytherapy dependent on tumor baseline characteristics and radiation dosage. Indices of tumor- and radiation-related complications were acceptable and comparable with those in the existing literature. The 5-year recurrence rate was 4% and the metastatic rate was 9.0 and 13.1% at 5 and 10 years, respectively. Overall, this study demonstrates that ruthenium-106 br -Abstract Truncated-

Wolfram-silicone implants as effective radiation shielding for ocular brachytherapy: dosimetric features and in vivo animal study on biocompatibility

Novel intraocular shielding device for eye plaque brachytherapy using magnetite nanoparticles: A proof-of-concept study using radiochromic film and Monte Carlo simulations

A comparison of the shielding effectiveness of silicone oil vitreous substitutes when used with Palladium‐103 and Iodine‐125 eye plaques

Treatment-Related Complications and Functional Results after Ruthenium-106 Brachytherapy in Small to Medium Size Uveal Melanomas (Part 2)

Ruthenium brachytherapie and sandwich therapy for medium sized uveal melanomas

In vivo evaluation of a nanotechnology-based microshunt for filtering glaucoma surgery

Monte Carlo dosimetry of Y-90 and Ru-106 /Rh-106 disk sources for ocular melanoma treatment: beta dose falloff study

Tumor- and Radiation-Related Complications after Ruthenium-106 Brachytherapy in Small to Medium Uveal Melanomas (Part 1)

Experimental Investigation of the Radiation Shielding Performance of a Newly Developed Silicon-Epoxy Resin Doped with WO3 Micro/Nanoparticles

Advanced Electrospun Composites Based on Polycaprolactone Fibers Loaded with Micronized Tungsten Powders for Radiation Shielding

Tumor Shape‐Specific Brachytherapy Implants by 3D‐Printing, Precision Radioactivity Painting, and Biomedical Imaging

Physical and Dosimetric Characterization of Silicone Rubber Bolus for Head Photon-Beam Radiotherapy

Development and preclinical test of a 32P containing PEEK foil aiming at urethral stricture prevention by LDR brachytherapy

A study of the irradiation technique used for the external beam radiotherapy of retinoblastoma

Analysis of safety and efficacy of proton radiotherapy for optic nerve sheath meningioma

In vitro and in vivo studies of ocular topically administered NLC for the treatment of uveal melanoma

Prognostic factors for surgical treatment of radiation-induced scleral necrosis after brachytherapy for uveal melanoma

Metastasis inhibition after proton beam, β- and γ-irradiation of melanoma growing in the hamster eye

Preclinical photon minibeam radiotherapy using a custom collimator: Dosimetry characterization and preliminary in-vivo results on a glioma model

Characterization of novel 3D‐printed metal shielding for brachytherapy applicators

A Long-Acting Curcumin Nanoparticle/In Situ Hydrogel Composite for the Treatment of Uveal Melanoma